0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Molecular Inhibitors of Growth Signals

      chapter-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Signal transduction associated with growth factor receptors typically mediates the activation of cell cycle promoting gene products or the inactivation of cell cycle checkpoints. These signals are frequently transduced through G-Protein pathways, kinase receptor pathways, or nuclear receptor pathways (Fig. 4.1), are dependent on proto-oncogenic transcription factors, and lead to the expression of Cyclins and Cyclin-Dependent Kinases (CDKs), which are drivers of the cell cycle (Fig. 4.2). Physiologically, growth signals are transient and entirely depend on the engagement of a growth factor receptor by its cognate ligand. Upon termination of this interaction, the growth signal ceases. Gain-of-function mutations in cancer keep the growth signal active, regardless of the presence of the transient growth factor-receptor interaction. Such deregulated signaling cascades are appropriate drug targets in the treatment of cancer.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint

          The proper segregation of sister chromatids in mitosis depends on bipolar attachment of all chromosomes to the mitotic spindle. We have identified the small molecule Hesperadin as an inhibitor of chromosome alignment and segregation. Our data imply that Hesperadin causes this phenotype by inhibiting the function of the mitotic kinase Aurora B. Mammalian cells treated with Hesperadin enter anaphase in the presence of numerous monooriented chromosomes, many of which may have both sister kinetochores attached to one spindle pole (syntelic attachment). Hesperadin also causes cells arrested by taxol or monastrol to enter anaphase within <1 h, whereas cells in nocodazole stay arrested for 3–5 h. Together, our data suggest that Aurora B is required to generate unattached kinetochores on monooriented chromosomes, which in turn could promote bipolar attachment as well as maintain checkpoint signaling.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

            HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers. Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease. Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-positive breast cancer but is active only in a subset of these tumors. Blocking HER-2 function by a small molecule kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-positive tumors. HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro. It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells. HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor. In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways. This leads to arrest at the G(1)-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation. In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule. On the basis of its favorable preclinical pharmacological profile, HKI-272 has been selected as a candidate for additional development as an antitumor agent in breast and other HER-2-dependent cancers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

              Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML). Here we examine predisposing factors underlying acquisition of KD mutations, evidence for acquisition of mutations before and during therapy, and whether the detection of a KD mutation universally implies resistance. We also provide a perspective on how the second-line Abl inhibitors dasatinib and nilotinib are faring in the treatment of imatinib-resistant CML, especially in relation to specific KD mutations. We discuss the growing importance of the multi-inhibitor-resistant 315T>I mutant and the therapeutic potential that a 315T>I inhibitor would have. Last, we assess the potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis.
                Bookmark

                Author and article information

                Journal
                978-3-319-13278-5
                10.1007/978-3-319-13278-5
                Molecular Therapies of Cancer
                Molecular Therapies of Cancer
                978-3-319-13277-8
                978-3-319-13278-5
                8 December 2014
                : 163-242
                Affiliations
                GRID grid.24827.3b, ISNI 0000000121799593, University of Cincinnati College of Pharmacy, ; Cincinnati, Ohio USA
                Article
                4
                10.1007/978-3-319-13278-5_4
                7122987
                22668db5-7db1-4903-b79f-9996a0a034ad
                © Springer International Publishing Switzerland 2015

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                Categories
                Article
                Custom metadata
                © Springer International Publishing Switzerland 2015

                acute myeloid leukemia,acute lymphocytic leukemia,chronic lymphocytic leukemia,fibroblast growth factor receptor,acute myelogenous leukemia

                Comments

                Comment on this article